Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd.
14 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
14
Trials led
9
Active
2,233
Total enrollment
10
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
7
Phase 2
4
Phase 3
3
Trials by status
Not yet recruiting
1
Recruiting
8
Completed
5
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseBMI ≥23Ph 3Recruiting207
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesBMI ≥28Ph 2Not yet recruiting200
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsBMI ≥28Ph 2Completed120
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects—Ph 1Recruiting80
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsBMI ≤28Ph 1Recruiting75
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionBMI 19-30Ph 1Completed34